ClinicalTrials.gg
CompletedNCT02211014Updated Jul 31, 2020Results posted

An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma

A Phase 1 interventional study of acalabrutinib in Multiple Myeloma (MM), sponsored by Acerta Pharma BV. Completed at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-31.

Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Multiple Myeloma by AstraZeneca — 8 open to participants now, 8 under way, 3 of them phase 3. Multiple Myeloma · AstraZeneca.

Enrollment
14th of 16
27 · median 104
Started
2015
with 1 other
Phase 1
6 of 16
1 open now
Registered
2nd of 16
by date

Among the 16 studies in Multiple Myeloma by AstraZeneca, this one is the 14th largest by enrollment, is one of 2 that started in 2015, is one of 6 in phase 1, and was the 2nd registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

8 of the 16 studies in Multiple Myeloma by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Multiple Myeloma by AstraZeneca, or all of them as a file.
02

Study summary

To characterize the safety profile of acalabrutinib with and without dexamethasone in subjects with relapsed or refractory Multiple Myeloma (MM)

03

Conditions studied

  • Multiple Myeloma (MM)

Browse trials for

Keywords

  • Bruton tyrosine kinase inhibitor
  • Btk
  • Multiple Myeloma
  • MM
  • ACP-196
  • acalabrutinib
  • Calquence
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women ≥ 18 years of age.
  • A confirmed diagnosis of MM, which has after, or been refractory to ≥ 1 prior therapy for MM, and is progressing at the time of study entry.
  • (ECOG) performance status of ≤ 2.
  • Agreement to use during the study and for 30 days after the last dose of study drugs if sexually active and able to bear or beget children.

Exclusion criteria

Exclusion Criteria:

  • A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of acalabrutinib, or put the study outcomes at undue risk
  • Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the Functional Classification
  • Malabsorption syndrome, disease significantly affecting gastrointestinal function, gastric bypass, resection of the stomach or small bowel, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.
  • Breast feeding or pregnant
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Acalabrutinib 100 mg twice daily (bid) continuously

    Drug: acalabrutinib

  • Experimental
    Cohort 2

    Acalabrutinib 100 mg bid continuously and 40 mg dexamethasone once weekly

    Drug: acalabrutinib

Interventions

06

What researchers measure

Primary outcomes

  1. Safety Profile of Acalabrutinib With and Without Dexamethasone

    AEs and SAEs were coded by system organ class (SOC) and preferred term (PT) based on the Medical Dictionary for Regulatory Activities (MedDRA) reporting system. All AEs summarized were treatment-emergent. Summaries were also presented by the severity of the AE (per Common Toxicity Criteria for Adverse Events \[CTCAE\]) and by relationship to study drug as assessed by the investigator. Events of clinical interest (ECIs) selected for dedicated analysis were evaluated using Standardized MedDRA Queries, where available, by SOC, or by Sponsor-defined baskets of MedDRA Adverse Event Grouped Terms (AEGTs). The following ECIs were summarized: Cardiac events (including a subset of atrial fibrillation), cytopenias (anemia, leukopenia, neutropenia, and thrombocytopenia), hemorrhage (including a subset of major hemorrhage), hepatic events, hypertension, infection, interstitial lung disease/pneumonitis, second primary malignancies (second primary malignancies excluding skin), tumor lysis syndrome.

    Time frame: From first dose of study drug up to Cycle 12 (48 weeks). Subjects who showed benefit from study drugs were allowed to continue until disease progression.

Secondary outcomes

  1. Pharmacokinetic (PK) Parameters Calculated for Acalabrutinib: AUC0-4, AUClast, AUCINF, Cmax, Tmax, λz, t1/2, CL/F, and Vz/F. PK Parameters Calculated for Dexamethasone: Tmax, Cmax, AUC0-4 and AUClast.

    The plasma PK of study drug was characterized using noncompartmental analysis. PK parameters were calculated whenever possible, from plasma concentrations of acalabrutinib. Missing dates or times could have been imputed for PK and pharmacodynamic (PD) samples if the missing values could be established with an acceptable level of accuracy based on other information obtained during the visit in question. If PK and PD sampling for a 33 Final Clinical Study Report Drug Substance Acalabrutinib Study Code ACE-MY-001 Edition Number 2 Date 31 October 2018 given subject was not performed according to protocol, the subject could have been excluded from the PK and PD analyses. The PK parameters were tabulated and summarized using descriptive statistics. For each PD variable, the concentration at each assessment was described. The change from baseline to each assessment was summarized. As appropriate the on treatment values were compared with the pretreatment baseline values using paired t-tests.

    Time frame: On Days 1 and 22: pre-dose, and at 0.5, 0.75, 1, 2, 4, and 6 hours after the morning dose. On Days 8, 15, and 28: pre-dose and 1 hour after the morning dose.

  2. Bruton Tyrosine Kinase (BTK) Occupancy

    The percent occupied BTK was calculated in each subject's peripheral blood mononuclear cells (PBMC) sample for each assessment timepoint using an ELISA-based method. Samples from 17 subjects met the criteria for data inclusion, having a dynamic range (signal to noise) of ≥5 for the Day 1 pre-dose timepoint. Acalabrutinib administered at 100 mg bid resulted in a median steady-state (Day 8) BTK target occupancy level of 95% and 98% for Cohort 1 and Cohort 2, respectively. The Days 28 and 56 assessments, both taken at pre-dose, were \>97% occupancy for each cohort. Intersubject variability was low, with 6 of 7 (86%) subjects in Cohort 1 and 4 of 5 (80%) subjects in Cohort 2 having \>90% BTK occupancy at steady-state trough (12h post-dose). The single subject in Cohort 2 with \<90% occupancy at Day 8 pre-dose did not take their Day 7 doses.

    Time frame: On Days 1 and 8: pre-dose and at 4 hours after the morning dose. On Days 28 and 56: morning pre-dose only.

  3. Response Assessed According to Guidelines Proposed by the International Myeloma Workshop Consensus Panel and European Group for Blood and Marrow Transplant

    Per EBMT: CR, negative immunofixation of serum and urine, disappearance of plasmacytomas and \< 5% plasma cells; Stringent complete response (SCR), CR + normal flow cytometry and absence of clonal plasma cells; Very good partial response (VGPR), Serum and urine M-protein detectable on immunofixation but not on electrophoresis or \> 90% reduction is serum and urine M protein; Partial response (PR), \> 50% reduction in serum M-protein and \> 90% reduction in 24 hour urine M-protein, \> 50% reduction in baseline soft tissue plasmacytoma; Minimal response (MR), 25-49% reduction of serum M-protein and 50-59% reduction in 24 hour urine M-protein, 25-49% reduction in plasmacytomas and no increase in lytic bone lesions; Stable disease (SD), not meeting criteria for CR, VGPR, MR, PR or progressive disease (PD); PD, increase of 25% or more from nadir in serum M-protein, urine M-protein, new or increased bone lesions or plasmacytomas, or hypercalcemia solely attributed to multiple myeloma.

    Time frame: From first dose of study drug up to Cycle 12 (48 weeks). Subjects who showed benefit from study drugs were allowed to continue until disease progression

07

Results

Posted May 13, 2020

Participant flow

Multicenter, open-label, randomized, parallel-group study to evaluate the safety, pharmacokinetics, pharmacodynamics and activity of acalabrutinib with/without dexamethasone in subjects with relapsed/refractory multiple myeloma in US and United Kingdom. 27 subjects enrolled into 2 cohorts. Enrollment was discontinued because of lack of efficacy.

Participant flow — Overall Study
MilestoneCohort 1Cohort 2
Started1314
Completed118
Not completed26
Withdrew: Adverse event02
Withdrew: Physician decision12
Withdrew: Started another cancer therapy10
Withdrew: Withdrawal by subject01
Withdrew: In agreement with patient, no benefit01

Outcome measures

PrimarySafety Profile of Acalabrutinib With and Without Dexamethasone

AEs and SAEs were coded by system organ class (SOC) and preferred term (PT) based on the Medical Dictionary for Regulatory Activities (MedDRA) reporting system. All AEs summarized were treatment-emergent. Summaries were also presented by the severity of the AE (per Common Toxicity Criteria for Adverse Events \[CTCAE\]) and by relationship to study drug as assessed by the investigator. Events of clinical interest (ECIs) selected for dedicated analysis were evaluated using Standardized MedDRA Queries, where available, by SOC, or by Sponsor-defined baskets of MedDRA Adverse Event Grouped Terms (AEGTs). The following ECIs were summarized: Cardiac events (including a subset of atrial fibrillation), cytopenias (anemia, leukopenia, neutropenia, and thrombocytopenia), hemorrhage (including a subset of major hemorrhage), hepatic events, hypertension, infection, interstitial lung disease/pneumonitis, second primary malignancies (second primary malignancies excluding skin), tumor lysis syndrome.

Time frame:
From first dose of study drug up to Cycle 12 (48 weeks). Subjects who showed benefit from study drugs were allowed to continue until disease progression.
Reported as:
Count of participants · Participants
Safety Profile of Acalabrutinib With and Without Dexamethasone
ParticipantsCohort 1Cohort 2
Treatment-emergent adverse events (TEAE)1314
Treatment-related TEAE77
SAE59
Treatment-related SAE12
TEAE leading to actions taken on study drug18
SecondaryPharmacokinetic (PK) Parameters Calculated for Acalabrutinib: AUC0-4, AUClast, AUCINF, Cmax, Tmax, λz, t1/2, CL/F, and Vz/F. PK Parameters Calculated for Dexamethasone: Tmax, Cmax, AUC0-4 and AUClast.

The plasma PK of study drug was characterized using noncompartmental analysis. PK parameters were calculated whenever possible, from plasma concentrations of acalabrutinib. Missing dates or times could have been imputed for PK and pharmacodynamic (PD) samples if the missing values could be established with an acceptable level of accuracy based on other information obtained during the visit in question. If PK and PD sampling for a 33 Final Clinical Study Report Drug Substance Acalabrutinib Study Code ACE-MY-001 Edition Number 2 Date 31 October 2018 given subject was not performed according to protocol, the subject could have been excluded from the PK and PD analyses. The PK parameters were tabulated and summarized using descriptive statistics. For each PD variable, the concentration at each assessment was described. The change from baseline to each assessment was summarized. As appropriate the on treatment values were compared with the pretreatment baseline values using paired t-tests.

Time frame:
On Days 1 and 22: pre-dose, and at 0.5, 0.75, 1, 2, 4, and 6 hours after the morning dose. On Days 8, 15, and 28: pre-dose and 1 hour after the morning dose.
Reported as:
Mean · percentage of CV
Pharmacokinetic (PK) Parameters Calculated for Acalabrutinib: AUC0-4, AUClast, AUCINF, Cmax, Tmax, λz, t1/2, CL/F, and Vz/F. PK Parameters Calculated for Dexamethasone: Tmax, Cmax, AUC0-4 and AUClast.
percentage of CVCohort 1 - Day 1Cohort 2 - Day 1Cohort 1 - Day 22Cohort 2 - Day 22
Cmax (ng/mL) - the maximum concentration observed524 ± 112437 ± 91.5271 ± 103607 ± 90.8
AUC (area under the curve)_0-4 (hr*ng/mL)604 ± 72.9621 ± 64390 ± 105766 ± 60.5
AUC_last (hr*ng/mL)638 ± 69.5675 ± 56.9423 ± 102812 ± 58.3
AUC_INF (infinity) (hr*ng/mL)754 ± 67.8732 ± 63.1411 ± 111826 ± 62.6
SecondaryBruton Tyrosine Kinase (BTK) Occupancy

The percent occupied BTK was calculated in each subject's peripheral blood mononuclear cells (PBMC) sample for each assessment timepoint using an ELISA-based method. Samples from 17 subjects met the criteria for data inclusion, having a dynamic range (signal to noise) of ≥5 for the Day 1 pre-dose timepoint. Acalabrutinib administered at 100 mg bid resulted in a median steady-state (Day 8) BTK target occupancy level of 95% and 98% for Cohort 1 and Cohort 2, respectively. The Days 28 and 56 assessments, both taken at pre-dose, were \>97% occupancy for each cohort. Intersubject variability was low, with 6 of 7 (86%) subjects in Cohort 1 and 4 of 5 (80%) subjects in Cohort 2 having \>90% BTK occupancy at steady-state trough (12h post-dose). The single subject in Cohort 2 with \<90% occupancy at Day 8 pre-dose did not take their Day 7 doses.

Time frame:
On Days 1 and 8: pre-dose and at 4 hours after the morning dose. On Days 28 and 56: morning pre-dose only.
Reported as:
Mean · percentage of occupied BTK
Bruton Tyrosine Kinase (BTK) Occupancy
percentage of occupied BTKCohort 1 - Day 1 PreCohort 2 - Day 1 PreCohort 1 - Day 1 PostCohort 2 - Day 1 PostCohort 1 - Day 8 PreCohort 2 - Day 8 PreCohort 1 - Day 8 PostCohort 2 - Day 8 PostCohort 1 - Day 28 PreCohort 2 - Day 28 PreCohort 1 - Day 56 PreCohort 2 - Day 56 Pre
Bruton Tyrosine Kinase (BTK) Occupancy0 ± 00 ± 098.5 ± 0.998.5 ± 1.393.2 ± 6.694.3 ± 8.898.6 ± 1.196.8 ± 4.897.6 ± 1.895.8 ± 5.595.7 ± 6.297.6 ± 1.3
SecondaryResponse Assessed According to Guidelines Proposed by the International Myeloma Workshop Consensus Panel and European Group for Blood and Marrow Transplant

Per EBMT: CR, negative immunofixation of serum and urine, disappearance of plasmacytomas and \< 5% plasma cells; Stringent complete response (SCR), CR + normal flow cytometry and absence of clonal plasma cells; Very good partial response (VGPR), Serum and urine M-protein detectable on immunofixation but not on electrophoresis or \> 90% reduction is serum and urine M protein; Partial response (PR), \> 50% reduction in serum M-protein and \> 90% reduction in 24 hour urine M-protein, \> 50% reduction in baseline soft tissue plasmacytoma; Minimal response (MR), 25-49% reduction of serum M-protein and 50-59% reduction in 24 hour urine M-protein, 25-49% reduction in plasmacytomas and no increase in lytic bone lesions; Stable disease (SD), not meeting criteria for CR, VGPR, MR, PR or progressive disease (PD); PD, increase of 25% or more from nadir in serum M-protein, urine M-protein, new or increased bone lesions or plasmacytomas, or hypercalcemia solely attributed to multiple myeloma.

Time frame:
From first dose of study drug up to Cycle 12 (48 weeks). Subjects who showed benefit from study drugs were allowed to continue until disease progression
Reported as:
Count of participants · Participants
Response Assessed According to Guidelines Proposed by the International Myeloma Workshop Consensus Panel and European Group for Blood and Marrow Transplant
ParticipantsCohort 1Cohort 2
sCR00
CR00
VGPR00
PR00
MR12
SD56
PD41
NE (not evaluable)35

Adverse events

Collected over Reported Adverse Events (AEs) include events starting on or after Day 0 and on or before Day 1210.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 12/13 (15.4%)5/13 (38.5%)13/13 (100%)
Cohort 24/14 (28.6%)9/14 (64.3%)14/14 (100%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventCohort 1Cohort 2
HypercalcaemiaMetabolism and nutrition disorders1/131/14
Hyperviscosity syndromeBlood and lymphatic system disorders1/130/14
Muscular weaknessMusculoskeletal and connective tissue disorders1/130/14
PainGeneral disorders1/130/14
SepsisInfections and infestations1/130/14
Skin massSkin and subcutaneous tissue disorders1/130/14
Urinary tract infectionInfections and infestations1/130/14
Acute kidney injuryRenal and urinary disorders0/131/14
Angina pectorisCardiac disorders0/131/14
BacteraemiaInfections and infestations0/131/14
Most frequent other events
Showing 10 of 40
Most frequent other events
EventCohort 1Cohort 2
AnaemiaBlood and lymphatic system disorders7/136/14
DiarrhoeaGastrointestinal disorders6/136/14
HeadacheNervous system disorders6/134/14
DyspnoeaRespiratory, thoracic and mediastinal disorders5/134/14
FatigueGeneral disorders4/132/14
CoughRespiratory, thoracic and mediastinal disorders4/130/14
Back painMusculoskeletal and connective tissue disorders1/134/14
NauseaGastrointestinal disorders3/133/14
ContusionPsychiatric disorders3/131/14
EpistaxisRespiratory, thoracic and mediastinal disorders3/131/14

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cohort 1Cohort 2Total
<=18 years000
Between 18 and 65 years9413
>=65 years41014
Age, Continuous
Age, Continuous(years)Cohort 1Cohort 2Total
Median60.0 (49 to 83)68.5 (53 to 78)65.0 (49 to 83)
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Total
Female6410
Male71017
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1Cohort 2Total
Hispanic or Latino101
Not Hispanic or Latino111425
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1Cohort 2Total
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American145
White11920
More than one race000
Unknown or Not Reported101
Region of Enrollment
Region of Enrollment(participants)Cohort 1Cohort 2Total
United States6713
United Kingdom7714
08

Study locations

3 sites
  • Baltimore, Maryland, United States
  • United Kingdom
    Leicester, United Kingdom
  • Guys and St Thomas' Hospital NHS Foundation Trust
    London, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2015 to primary completion in Apr 2019, 50 months.

Results were first posted in May 2020, 1 year after primary completion.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's 50 months is above that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2014
First posted
Aug 7, 2014
StartActual
Feb 2015
Primary completionActual
Apr 26, 2019
CompletionActual
Apr 26, 2019
Results first posted
May 13, 2020
Last update
Jul 31, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02211014
Lead sponsor
Acerta Pharma BV
Collaborators
Acerta Pharma, LLC
Responsible party
Sponsor
First posted
Aug 7, 2014
Start date
Feb 2015
Primary completion
Apr 26, 2019
Completion
Apr 26, 2019
Results posted
May 13, 2020
Last update
Jul 31, 2020

Study contacts

Acerta Clinical Trials
study director · 1-888-292-9613

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acalabrutinib

Start the discussion